Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H9N3O2S2 |
Molecular Weight | 255.317 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=CC=C(C=C1)S(=O)(=O)NC2=NC=CS2
InChI
InChIKey=JNMRHUJNCSQMMB-UHFFFAOYSA-N
InChI=1S/C9H9N3O2S2/c10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9/h1-6H,10H2,(H,11,12)
DescriptionSources: http://www.sciencedirect.com/science/article/pii/B9780080552323633343 | http://www.rxlist.com/sultrin-drug.htmCurator's Comment: Description was created based on several sources, including http://www.mims.com/india/drug/info/sulfathiazole?type=full&mtype=generic#Indications
Sources: http://www.sciencedirect.com/science/article/pii/B9780080552323633343 | http://www.rxlist.com/sultrin-drug.htm
Curator's Comment: Description was created based on several sources, including http://www.mims.com/india/drug/info/sulfathiazole?type=full&mtype=generic#Indications
Sulfathiazole is a short-acting sulfonamide with properties similar to those of sulfamethoxazole. It is now rarely used systemically due to its toxicity. Sulfathiazole is used with other sulfonamides, usually sulfabenzamide and sulfacetamide, in preparations for the topical treatment of vaginal infections and is also used with other drugs in the treatment of skin infections. Sulfathiazole sodium has been applied topically with other drugs in the treatment of eye infections. Sulfathiazole interferes with nucleic acid synthesis in microorganisms by blocking the conversion of p-aminobenzoic acid to the coenzyme dihydrofolic acid.It has properties similar to sulfamethoxazole.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16561456 |
|||
Target ID: GO:0046656 |
|||
Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26428163 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Sulfathiazole Approved UseVaginal infections |
Doses
Dose | Population | Adverse events |
---|---|---|
1 g 6 times / day multiple, oral Recommended Dose: 1 g, 6 times / day Route: oral Route: multiple Dose: 1 g, 6 times / day Sources: |
unhealthy n = 100 Health Status: unhealthy Condition: infection Population Size: 100 Sources: |
Disc. AE: Dermatitis, Nausea and vomiting... Other AEs: Nitrogen retention, Hematuria... AEs leading to discontinuation/dose reduction: Dermatitis (9%) Other AEs:Nausea and vomiting (6%) Nitrogen retention (1%) Sources: Hematuria (1%) Drug fever (2%) Burning eyes (2%) Conjunctival injection (1%) Anemia (1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anemia | 1% | 1 g 6 times / day multiple, oral Recommended Dose: 1 g, 6 times / day Route: oral Route: multiple Dose: 1 g, 6 times / day Sources: |
unhealthy n = 100 Health Status: unhealthy Condition: infection Population Size: 100 Sources: |
Conjunctival injection | 1% | 1 g 6 times / day multiple, oral Recommended Dose: 1 g, 6 times / day Route: oral Route: multiple Dose: 1 g, 6 times / day Sources: |
unhealthy n = 100 Health Status: unhealthy Condition: infection Population Size: 100 Sources: |
Hematuria | 1% | 1 g 6 times / day multiple, oral Recommended Dose: 1 g, 6 times / day Route: oral Route: multiple Dose: 1 g, 6 times / day Sources: |
unhealthy n = 100 Health Status: unhealthy Condition: infection Population Size: 100 Sources: |
Nitrogen retention | 1% | 1 g 6 times / day multiple, oral Recommended Dose: 1 g, 6 times / day Route: oral Route: multiple Dose: 1 g, 6 times / day Sources: |
unhealthy n = 100 Health Status: unhealthy Condition: infection Population Size: 100 Sources: |
Burning eyes | 2% | 1 g 6 times / day multiple, oral Recommended Dose: 1 g, 6 times / day Route: oral Route: multiple Dose: 1 g, 6 times / day Sources: |
unhealthy n = 100 Health Status: unhealthy Condition: infection Population Size: 100 Sources: |
Drug fever | 2% | 1 g 6 times / day multiple, oral Recommended Dose: 1 g, 6 times / day Route: oral Route: multiple Dose: 1 g, 6 times / day Sources: |
unhealthy n = 100 Health Status: unhealthy Condition: infection Population Size: 100 Sources: |
Nausea and vomiting | 6% Disc. AE |
1 g 6 times / day multiple, oral Recommended Dose: 1 g, 6 times / day Route: oral Route: multiple Dose: 1 g, 6 times / day Sources: |
unhealthy n = 100 Health Status: unhealthy Condition: infection Population Size: 100 Sources: |
Dermatitis | 9% Disc. AE |
1 g 6 times / day multiple, oral Recommended Dose: 1 g, 6 times / day Route: oral Route: multiple Dose: 1 g, 6 times / day Sources: |
unhealthy n = 100 Health Status: unhealthy Condition: infection Population Size: 100 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Quantitative determination of trace concentrations of tetracycline and sulfonamide antibiotics in surface water using solid-phase extraction and liquid chromatography/ion trap tandem mass spectrometry. | 2004 |
|
Quantitative analysis of twelve sulfonamides in honey after acidic hydrolysis by high-performance liquid chromatography with post-column derivatization and fluorescence detection. | 2004 Aug 20 |
|
Sequence analysis and characterization of sulfonamide resistance plasmid pRF-1 from Salmonella enterica serovar Choleraesuis. | 2004 Nov |
|
Serum activity/concentration profiles of a sustained-released formulation of sulphathiazole-trimethoprim (2.5:1) in calves. | 2004 Nov 20 |
|
Spectroscopic features of radiolytic intermediates induced in gamma irradiated sulfatiazole: an ESR study. | 2004 Nov 5 |
|
Determination of sulfonamide residues in the tissues of food animals using automated precolumn derivatization and liquid chromatography with fluorescence detection. | 2004 Sep-Oct |
|
Enumeration and antibiotic resistance patterns of fecal indicator organisms isolated from migratory Canada geese (Branta canadensis). | 2005 Apr |
|
Water adsorption kinetics and contact angles of pharmaceutical powders. | 2005 Apr |
|
Flow-through sensor with Fourier transform Raman detection for determination of sulfonamides. | 2005 Dec |
|
Surface runoff and transport of sulfonamide antibiotics and tracers on manured grassland. | 2005 Jul-Aug |
|
Evaluating the biodegradability of sulfamethazine, sulfamethoxazole, sulfathiazole, and trimethoprim at different stages of sewage treatment. | 2005 Jun |
|
Aging and microwave effects on alginate/chitosan matrices. | 2005 Jun 2 |
|
[Nuclease biosynthesis and growth of Serratia marcescens in the presence of 2-(p-aminobenzenesulfonamide)-thiazole]. | 2005 May-Jun |
|
Characterization of polymorphic solid-state changes using variable temperature X-ray powder diffraction. | 2005 Sep 1 |
|
Analysis of Pneumocystis jirovecii DHPS alleles implicated in sulfamethoxazole resistance using an Escherichia coli model system. | 2005 Spring |
|
Synthesis, characterization, and biotoxicity of N N donor sulphonamide imine silicon(IV) complexes. | 2006 |
|
Evaluation of changes in antimicrobial susceptibility patterns of Pasteurella multocida subsp multocida isolates from pigs in Spain in 1987-1988 and 2003-2004. | 2006 Apr |
|
Multiresidue determination of sulfonamides in edible catfish, shrimp and salmon tissues by high-performance liquid chromatography with postcolumn derivatization and fluorescence detection. | 2006 Aug 18 |
|
Antibacterial, antifungal and cytotoxic properties of novel N-substituted sulfonamides from 4-hydroxycoumarin. | 2006 Dec |
|
Changes in antibacterial activity of triclosan and sulfa drugs due to photochemical transformations. | 2006 Jun |
|
Influence of endotoxin induced fever on the pharmacokinetics of intramuscularly administered cefepime in rabbits. | 2006 Jun |
|
Dissecting the behavior of a promiscuous solvate former. | 2006 Mar 20 |
|
Polymorph farming of acetaminophen and sulfathiazole on a chip. | 2006 Nov |
|
Characterization of temperature-induced phase transitions in five polymorphic forms of sulfathiazole by terahertz pulsed spectroscopy and differential scanning calorimetry. | 2006 Nov |
|
Antibiotic Transport via Runoff and Soil Loss. | 2006 Nov-Dec |
|
14N nuclear quadrupole resonance of some sulfa drugs. | 2006 Sep |
|
Exhaustive extraction of sulfonamide antibiotics from aged agricultural soils using pressurized liquid extraction. | 2006 Sep 22 |
|
Assessment of biofilm cell removal and killing and biocide efficacy using the microtiter plate test. | 2007 |
|
Aquatic toxicity of acetaminophen, carbamazepine, cimetidine, diltiazem and six major sulfonamides, and their potential ecological risks in Korea. | 2007 Apr |
|
Influence of ethanolic extract of Jasminum grandflorum linn flower on wound healing activity in rats. | 2007 Apr-Jun |
|
Pressurized liquid extraction combined with capillary electrophoresis-mass spectrometry as an improved methodology for the determination of sulfonamide residues in meat. | 2007 Aug 3 |
|
Performance of blue-yellow screening test for antimicrobial detection in ovine milk. | 2007 Dec |
|
A longitudinal study of Salmonella shedding and antimicrobial resistance patterns in North Dakota feedlot cattle. | 2007 Feb |
|
Solubility measurement of polymorphic compounds via the pH-metric titration technique. | 2007 Feb 7 |
|
Sorption of the veterinary antimicrobial sulfathiazole to organic materials of different origin. | 2007 Jan 1 |
|
Determination of sulfonamide compounds in sewage and river by mixed hemimicelles solid-phase extraction prior to liquid chromatography-spectrophotometry. | 2007 Jan 19 |
|
Simultaneous determination of 17 sulfonamides and the potentiators ormetoprim and trimethoprim in salmon muscle by liquid chromatography with tandem mass spectrometry detection. | 2007 Jan-Feb |
|
Time and pH-dependent sorption of the veterinary antimicrobial sulfathiazole to clay minerals and ferrihydrite. | 2007 Jul |
|
Structural analysis of photo-degradation in thiazole-containing compounds by LC-MS/MS and NMR. | 2007 Jul 27 |
|
Determination of sulfonamides in milk after precolumn derivatisation by micellar liquid chromatography. | 2007 Jun 19 |
|
Evaluation of carbon nanotubes as a solid-phase extraction adsorbent for the extraction of cephalosporins antibiotics, sulfonamides and phenolic compounds from aqueous solution. | 2007 Jun 26 |
|
Determination of 10 sulfonamide residues in meat samples by liquid chromatography with ultraviolet detection. | 2007 Mar-Apr |
|
Depth distribution of sulfonamide antibiotics in pore water of an undisturbed loamy grassland soil. | 2007 Mar-Apr |
|
Crystal polymorphism of pharmaceuticals: probing crystal nucleation at the molecular level. | 2007 Oct |
|
Rapid simultaneous determination of 14 sulfonamides in wastewater by liquid chromatography tandem mass spectrometry. | 2007 Oct |
|
[Simultaneous determination of nine sulfonamide residues in milk using solid phase extraction and high performance liquid chromatography]. | 2007 Sep |
|
Flow-through optosensor combined with photochemically induced fluorescence for simultaneous determination of binary mixtures of sulfonamides in pharmaceuticals, milk and urine. | 2007 Sep 26 |
|
Immunochemical assays for direct sulfonamide antibiotic detection in milk and hair samples using antibody derivatized magnetic nanoparticles. | 2008 Feb 13 |
|
The use of sulfathiazole in the treatment of subacute and chronic osteomyelitis : Frank D. Dickson MD (1882-1964), Rex L. Diveley MD, Richard Kiene MD. The 4th president of the AAOS 1935 (FDD). | 2008 Jan |
|
Environmental levels of ultraviolet light potentiate the toxicity of sulfonamide antibiotics in Daphnia magna. | 2008 Jan |
Patents
Sample Use Guides
Adult: Cream (Sulphathiazole 34.2 mg/g, sulphacetamide 28.6 mg/g, sulphabenzamide 37 mg/g and urea 6.4 mg/g): 5g is applied intra-vaginally bid for 4 to 6 days. Thereafter the dosage may be reduced to one-half or one-quarter.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7130069
25 ug/ml of Sulfathiazole is required for inhibition of in vitro cellulose digestion and volatile fatty acid production by ruminal microorganisms.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
77903
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
||
|
WHO-VATC |
QJ01EQ07
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
||
|
WHO-ATC |
J01EB07
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
||
|
WHO-VATC |
QD06BA02
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
||
|
NCI_THESAURUS |
C29739
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
||
|
WHO-ATC |
D06BA02
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000083763
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
1636504
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
31812
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
6052-33-1
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
SUPERSEDED | |||
|
C66571
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
859037-27-7
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
SUPERSEDED | |||
|
158269-46-6
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
SUPERSEDED | |||
|
428
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
m10344
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | Merck Index | ||
|
10193
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | RxNorm | ||
|
Y7FKS2XWQH
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
DTXSID8026068
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
4380
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
2527
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
200-771-5
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
DB06147
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
Y7FKS2XWQH
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
SULFATHIAZOLE
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
SUB10731MIG
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
5340
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
683531
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL437
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
C005312
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
9337
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY | |||
|
72-14-0
Created by
admin on Fri Dec 15 15:01:46 GMT 2023 , Edited by admin on Fri Dec 15 15:01:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)